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ABSTRACT 
Resistance exercise induces skeletal muscle hypertrophy via repeated exercise bouts. 
The increased muscle protein synthesis together with altered muscle protein 
degradation contribute to the adaptation of muscle mass. The number of ribosomes 
dictates the protein synthetic capacity of muscle. Therefore, the regulation of de novo 
ribosome synthesis is of great value for maintaining skeletal muscle mass and muscle 
hypertrophy. The main objective of this thesis is to examine the molecular 
mechanisms regulating ribosome biogenesis in response to different stimuli. 
In Paper I, we investigated skeletal muscle gene expression following acute and 
chronic resistance exercise. By examining the phosphorylation of rpS6Ser235/236 as a 
marker for mTOR signaling pathway activated, we found that mTOR was activated 
after acute resistance exercise but attenuated after 12 weeks of resistance exercise. 
Similar to mTOR pathway, the 45S pre-rRNA and gene expression of c-Myc showed 
a dramatic increase after acute resistance exercise but reduced in response to acute 
resistance exercise following 12 week of resistance exercise. These findings suggest 
that the hypertrophy associated gene expression profile is not correlated with the 
developing muscle phenotype. 
In Paper II, we exposed mice to 10% CO2 and 21% O2 in order to induce a 
hypercapnic environment and examined the responses of anabolic genes and 
proteolytic systems. Hypercapnia caused decreases in muscle fiber diameter, protein 
content and force production, which indicated muscle atrophy. Similarly, the 
increased level of CO2 caused thinner myotubes, lower protein content and decreased 
anabolic signaling such as rDNA transcription rate. Meanwhile, the activity of 
ubiquitin-proteasome system was increased due to the increased AMPK-FOXO3-
MuRF1 pathway. These results suggest that the coordination of protein synthesis and 
degradation is of great importance in the dynamic process of protein modification. 
To further understand the regulation of muscle hypertrophy at the molecular level, we 
generated conditional skeletal muscle specific c-Myc knock out mice. In Paper III, 
we found that the mice lacking c-Myc displayed normal post-natal skeletal muscle 
development in terms of body weight, muscle weight, RNA content and rDNA 
transcription rate when compared to control mice. To challenge the c-Myc knock out 
mice in a rapid growth situation, we performed synergist ablation of the 
gastrocnemius and soleus muscles to induce compensatory hypertrophy of the plantar 
flexor muscles. The c-Myc conditional knock out mice showed normal hypertrophic 
response, which indicated that c-Myc is dispensable for hypertrophic growth in 
terminally differentiated cells. We further confirmed this finding by blocking c-Myc 
function via chemical inhibitors in C2C12 myotubes. However, inhibiting c-Myc by 
siRNA or loss of its function by chemical inhibitor in proliferating C2C12 myoblast 
suggested a different role by blocking cell proliferation and decrease rDNA 
transcription. Therefore, we suggest a cell stage-specific role of c-Myc in the 
regulation of growth/proliferation and rDNA transcription in the myogenic cell lines. 
To further understand the regulation of ribosome biogenesis during muscle 
hypertrophy, we focused on the mTOR pathway due to its regulatory role in protein 
homeostasis. In Paper IV, the mature C2C12 myotubes were stimulated with high 
concentration of serum to induce myotube hypertrophy. Increased mTOR signaling 
was detected during hypertrophy and the inhibition of mTOR prevented the 
hypertrophic response. When inhibiting the function of mTOR, rDNA transcription 
rate was decreased as well as the mTOR/rDNA promoter binding, which indicated a 
role for nuclear mTOR in the regulation of rDNA transcription. Furthermore, 
chemical inhibition of RNA Polymerases I prevented rRNA accumulation and 
myotubes hypertrophy, suggesting that intact Pol I mediated transcription was 
necessary for muscle hypertrophy. 
In conclusion, this thesis investigates the regulation of skeletal muscle hypertrophy by 
different mechanisms. It highlights the importance of ribosome biogenesis during 
skeletal muscle hypertrophy.  
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1 INTRODUCTION 
Skeletal muscle is the most abundant tissue in the human body, which transforms 
chemical energy into movement. Movement is essential for life in every aspect of 
health thus the normal physiology of skeletal muscle plays a fundamental role in 
health and disease. Under the conditions of neurological, infectious, metabolic, 
oncological, and many other disorders, loss of skeletal muscle mass (atrophy or 
wasting) significantly decreases quality of life and increases morbidity and mortality. 
Currently, the only efficient yet safe way to increase muscle mass in human is via 
resistance exercise (RE). RE training can increase muscle mass via repeated periods of 
augmented protein translation, resulting in protein accretion and muscle hypertrophy. 
Several evidences have been shown that in many disorders like Type 2 diabetes and 
chronic kidney disease (Ikizler 2011; Nader and Lundberg 2009; Lundberg and Nader 
2008), RE can be an optional treatment besides the traditional medicine. 
Therefore, the work described in this thesis focuses on the molecular mechanisms that 
controlling skeletal muscle mass, and more specifically the regulation of de novo 
synthesis of ribosomes. These findings may provide potential targets for the 
development of effective therapies and pharmacological agents aiming at preventing 
loss of skeletal muscle mass. 
1.1 SKELETAL MUSCLE AND RESISTANCE EXERCISE 
The skeletal muscle system represents one of the largest systems in the body and 
accounts for more than 40% of the body mass (Hoppeler and Fluck 2002). Skeletal 
muscle is composed of elongated cells, which are known as muscle fibers. Unlike 
other cell types, muscle fibers contain several nuclei, which are all located beneath the 
plasma membrane (sarcolemma). The satellite cells, which have only one nucleus, are 
located outside of the sarcolemma but within the basal lamina (basement membrane). 
Mature and functional muscle fibers are parallel to their neighbors and are arranged in 
bundles called fascicles and enclosed by connective tissue. Each muscle fiber is 
surrounded by a capillary network that supplies the cell with the necessary oxygen 
and nutrients required by the activated skeletal muscle. As the most abundant 
myofibrillar proteins, the contractile proteins myosin and actin occupy about 80% of 
the muscle fiber volume in human skeletal muscle (Eisenberg 2011). Due to this high 
protein content, the skeletal muscle represents as a reservoir of protein at the 
organismal level under the conditions of low nutrient availability (Finn and Dice 
2006). 
During skeletal muscle contractions, the glucose stored in the muscle is utilized by 
mitochondria. Thus skeletal muscle is also considered as primary insulin target as its 
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marked impact on glucose homeostasis (Richter and Hargreaves 2013). Meanwhile, 
many other events like phosphorylation of protein kinases or activation/deactivation 
of various groups of genes contribute to this adaptation to training (Bengt Saltin 
1983). Thus a systematic profile on the expression patterns of genes may help people 
to understand the mechanism for the muscle adaptation to training. 
The history of resistance training is often traced back to ancient Greece and the legend 
of Milo of Croton. Nowadays, the fact that RE training increases muscle mass and 
strength has become common knowledge and the beneficial effects on health in 
general are well described. Based on this knowledge, athletes can improve sport-
specific performance in a more efficient approach and the general population may 
promote health, lean body mass and general fitness. Different mode, intensity, 
frequency and the volume of training can modulate acute resistance exercise. 
(American College of Sports 2009). The end-point results could also vary depending 
on the possible programs. Therefore, understanding the regulation of muscle under 
various conditions/time points is of great value for improving human health. 
1.2  SKELETAL MUSCLE DEVELOPMENT AND HYPERTROPHIC GROWTH 
From embryo to adulthood, the skeletal muscle mass are continuously increased. In 
skeletal muscle research, evidence of increased muscle mass can be either revealed in 
the form of increases in muscle size examined by magnetic resonance imaging (MRI), 
computer tomography (CT) or ultrasound (US). Alternatively, skeletal muscle mass 
can be indirectly evaluated by measuring protein content or distribution of cross-
section area (CSA) assessed in muscle biopsy material. The general explanation for 
the increase in CSA was mainly due to the increases in fiber size and/or fiber number 
(hyperplasia) depending on different development stage (Macdougall 2003). During 
fetal development, the most important factor contributing to muscle growth is an 
increased fiber number. Several determination factors such as MyoD, Myogenic 
regulatory factor 5 (Myf5), Myogenin (MYOG) and the Myocyte enhancer factor-
2(Mef2) are expressed in a time-dependent manner in the skeletal muscle progenitor 
cells (Buckingham et al. 2003). An increase in skeletal muscle fiber number is thus 
preceded by proliferation and differentiation of these progenitor cells. Both muscle 
mass and the number of myonuclei per fiber increased rapidly postpartum due to the 
accumulation of proteins and fusion of satellite cells (Layman, Hegarty, and Swan 
1980). Skeletal muscle fiber number remains stable from roughly 3 weeks of age until 
adulthood (White et al. 2010).  
In adult skeletal muscle, hypertrophy predominantly relies on an increased amount of 
contractile proteins, which leads to an increase in the size of preexisting muscle fibers 
(CSA) and their consequent force production (Macdougall 2003). However, evidence 
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in favor of an increased fiber number following chronic RE in humans has been 
presented (Larsson and Tesch 1986) and an increased number of myonuclei per fiber 
has been observed after mechanical overload (Bruusgaard et al. 2010). One potential 
explanation underlying both observations is that proliferation of satellite cells is 
responsible for these events (Allen, Roy, and Edgerton 1999). However, conditional 
deletion of satellite cells in skeletal muscle doesn’t affect the ability of skeletal muscle 
to hypertrophy (Jackson et al. 2012; McCarthy et al. 2011). This result indicates that 
satellite cell proliferation and fusion with mature muscle fibers are not necessary for 
hypertrophic growth. Therefore, to understand the regulation of hypertrophic growth 
of preexisting skeletal muscle fibers, further studies on synthesis and accumulation of 
protein become essential.  
1.3 PROTEIN HOMEOSTASIS IN SKELETAL MUSCLE 
The protein homeostasis is of great importance for maintaining skeletal muscle 
function. It has been determined that as much as 280g of proteins are turned over per 
day in males weighing 70kg (Mitch and Goldberg 1996). Protein synthesis and protein 
degradation are dynamic processes that are simultaneously active, but in most of the 
situations they need to be coordinately regulated, depending on the circumstances, to 
balance the protein turnover. When overall rates of protein synthesis exceed the rate 
of protein degradation, the net protein turnover is positive resulting in accumulation of 
protein and skeletal muscle hypertrophy. Both protein synthesis (Chesley et al. 1992) 
and degradation (Phillips et al. 1997) are upregulated during acute resistance 
exercise (Kumar et al. 2009) or serum stimulation in cell (Zhang et al. 2014). 
Therefore a tightly regulated mechanism, which coordinates protein synthesis with 
protein degradation, is important to maintain amino acid and protein homeostasis, as 
any imbalance may disrupt cell or tissue function and/or morphology.  
Protein synthesis begins with the transcription of DNA into mRNA, which then trans-
located and translated into amino acid chains by ribosomes followed by post-
translational modifications and protein folding. Both translational efficiency and 
translational capacity are essential for the adaptation of protein synthesis rate. The rate 
of protein synthesis in skeletal muscle has been shown to be proportional to muscle 
RNA content (Millward et al. 1973). Considering that more than 80% of cellular RNA 
is made up of ribosomal RNA (rRNA), a sufficient amount of ribosomes are essential 
to guarantee efficient protein synthesis. Previous studies demonstrate that muscle 
RNA content increases by increased loading (Goldberg et al. 1975; Chaillou et al. 
2013; Goodman et al. 2011) or following RE (Haddad, Baldwin, and Tesch 2005) and 
decreases by denervation (Haddad et al. 2003; Machida et al. 2012) or healthy aging 
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(Galavazi and Szirmai 1971). Therefore, the rRNA content dedicate to the protein 
translational capacity, which further contribute to protein homeostasis.  
Protein degradation, on the other hand, is primarily believed to remove damaged and 
abnormal proteins and prevent their accumulation. Previous studies investigating the 
anabolic response of skeletal muscle to mechanical loading have often overlooked 
degradation in favor of synthesis measurements, as protein degradation has been 
considered to be more associated with pathological states than with normal cellular 
functioning. This line of reasoning was supported by the hypothesis that protein 
degradation is the principle mechanism underlying muscle atrophy and weakness 
(Bell, Al-Khalaf, and Megeney 2016). Removing of proteins, together with other 
function of protein degradation, such as sources of amino acids or regulation of 
cellular metabolism, are equally important in healthy muscle. In skeletal muscle, 
different proteins are degraded at different rates depending on the function and/or the 
relevant proteolytic pathway. Ubiquitin-proteasome (UP) mediated protein 
degradation targets short-lived proteins as well as autophagy-lysosome mediated 
protein degradation targeted long-lived proteins (Sandri 2013; Lilienbaum 2013). 
Dysfunction of the UPS and/or ubiquitin presenting proteins has been reported to 
reduce skeletal muscle atrophy (Caron et al. 2011) and induce muscle growth defects 
(Kitajima et al. 2014). Thus maintaining normal functions of protein degradation is 
essential for skeletal muscle. 
Among many signaling networks, which participate in the regulation of protein 
homeostasis, the mTOR pathway is believed to represent a central signaling hub that 
synchronizes anabolic input from various sources and coordinately regulates both 
protein synthesis and degradation. RE has been shown to activate PI3K/mTOR/S6K 
(Al-Shanti and Stewart 2009; Glass 2010; Hulmi et al. 2009; Schiaffino et al. 2013) 
due to the multilevel regulatory functions of mTOR pathway. The role of mTOR will 
be further discussed in section 1.4.5. 
1.4 RIBOSOME BIOGENESIS 
Ribosomes are large ribonucleo-protein complexes measuring 200-250 Å in diameter 
and with an approximate mass of 4 MDa. Ribosomes are composed of two subunits 
with each of them containing rRNAs and ribosomal proteins (RP). In eukaryotes, the 
large subunit (60S) is composed of 28S rRNA (~4700 nucleotides), 5S rRNA (~120 
nucleotides) and an additional 5.8S rRNA (~160 nucleotides) together with 49 
ribosomal proteins. The small subunit (40S) is composed of 18S rRNA (~1900 
nucleotides) and 33 proteins (Thomson, Ferreira-Cerca, and Hurt 2013). Ribosomal 
subunits are assembled in the nucleus and must be transported to the cytoplasm for 
their final maturation. The synthesis of protein from mRNA occurs on the ribosome in 
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the cytoplasm. The small unit (40S) binds to 5’ end of mRNA then recognizes the 
correct tRNA, which charged with amino acid. Polypeptide chain elongates by the 
next tRNA binding to ribosome and catalyzed by the 60S subunit.  
The amount of rRNA, as represented by total RNA content, has been reported 
increased following mechanical loading in animal models (Chaillou et al. 2013; 
Goodman et al. 2011; Miyazaki et al. 2011) or after resistance exercise in human 
(Haddad 2005). At the onset of skeletal muscle hypertrophy, rRNA content has been 
reported to increase approximately 2-fold (von Walden et al. 2012). It has also been 
shown that 24h to 48h serum stimulation in a rodent myogenic cell line (L6) results in 
a continuous increase in rRNA content (Nader, McLoughlin, and Esser 2005). On the 
contrary, inactivity, denervation and even healthy aging is associated with reduced 
rRNA content in skeletal muscle (Babij and Booth 1988; Galavazi and Szirmai 1971; 
Haddad, Baldwin, and Tesch 2005; Machida et al. 2012). Together these findings 
support an important role for ribosome content in influencing protein 
synthesis/accumulation and thereby the regulation of skeletal muscle mass. 
 
 
Fig. 1 Schematics demonstrating the components of the ribosome and the organization 
of the 45S rDNA gene.  
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1.4.1 Ribosome biogenesis 
Ribosome biogenesis is a very energy consuming cellular activity and clearly a 
process of extraordinary complexity (Warner 1999; Fromont-Racine et al. 2003; 
Henras et al. 2008; Kressler, Hurt, and Bassler 2010). It requires the coordinated 
activity of all three nuclear RNA polymerases (RNA Pol I/II/III) present in eukaryotic 
cells. The rate-limiting step in ribosome biogenesis is considered to be RNA 
polymerase I (Pol I) dependent transcription, which is exclusively responsible for the 
transcription of the 45S precursor rRNA. This long precursor transcript is 
subsequently processed into the mature 18S, 5.8S and 28S rRNA species. RNA Pol I 
mediated transcription accounts for about 60% of overall transcriptional activity in the 
cell. RNA polymerase II (Pol II) transcribes all the mRNAs in the nucleus, including 
those coding for ribosomal proteins. RNA polymerase III (Pol III) is required for the 
transcription of 5S rRNA and tRNA. Counting together with all the rRNA and 
ribosomal proteins, more than 150 transacting factors and approximately one hundred 
small nucleolar RNAs (snoRNAs) involved in the maturation pathway of ribosomes 
(Kressler, Linder, and de La Cruz 1999; Venema and Tollervey 1999; Fatica and 
Tollervey 2002; Tschochner and Hurt 2003).  
1.4.2 Polymerase I dependent 45S rDNA transcription 
45S rDNA genes have about 400 copies per diploid genome in human and mice, and 
are located on 4-5 chromosomes (Moss et al. 2007). The nucleolus can organize 
around the rRNA genes during interphase, thus the regions where 45S genes are 
tandemly repeated were termed as nucleolar organizer region (NOR) or so called 45S 
rDNA sites (Lam, Trinkle-Mulcahy, and Lamond 2005; Shaw and Doonan 2005). It 
not clear that if NOR contribute to the regulation of cell proliferation but in non-
proliferating cells it has been reported that the number of NORs is a marker of 
ribosomal protein synthesis activity in non-proliferating cells in skeletal muscle (Jozsa 
et al. 1993). 
The length of the rDNA repeat is about 43 kb in human or 45 kb in mouse. The 
intergenic spacer (IGS) region is located between the transcribed regions and 
transcription termination signals are existed at both ends of IGS (Moss and 
Stefanovsky 1995; Hannan and Rothblum 1995). The function of the IGS is not 
entirely understood but it contains elements that can regulate or enhance the rDNA 
replication and transcription (Doelling, Gaudino, and Pikaard 1993). Based on the 
differences on function, the rDNA promoter can be divided into two distinct domains, 
the core promoter element (CPE) – with respect to the transcription initiation site, and 
the upstream control element (UCE) – essential for formation of the pre-initiation 
complex and promoting efficient rRNA transcription (Grozdanov, Georgiev, and 
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Karagyozov 2003). Among different species, the sequence of the rDNA promoter 
does not show significant sequence identity. However there is a high level of 
conservation among species regarding the functional elements of the 45S rDNA gene 
(Paule and White 2000).  
The transcription of rDNA begins with the promoter region and then continues with 
the external transcribed spacer (ETS), 18S rRNA, the internal transcribed spacer 1 
(ITS1), 5.8s rRNA, ITS2 and 28S rRNA. The transcribed pieces generated from the 
rDNA varies from ~8 kb (yeast, Drosphila and Xenopus) to ~13 kb (mammals), partly 
contributed by the difference in the length of ETS and ITS (Moss and Stefanovsky 
1995; Hannan and Rothblum 1995; Larson, Zahradka, and Sells 1991). At the onset of 
rDNA transcription, the pre-initiation complex (PIC), which is formed by several 
transcription factors, is recruited and assembled together with Pol I on the CPE. This 
protein complex is necessary for the initiation of 45S pre-rRNA synthesis. Within this 
multi-protein complex, the ribosomal DNA transcription factor Rrn3 (also referred to 
as Transcription Initiation Factor I (TIF-I) A), Selectivity Factor 1 (SL1), and 
Upstream Binding Factor (UBF) are essential for ribosome gene transcription in 
mammals. Once the transcription of 45S pre-rRNA precursor is complete, the 
transcript is processed into 18S, 5.8S and 28S following a number of events (Moss et 
al. 2007). There are several alternative processing pathways but a total of 4 sequences, 
two external and two internal, have to be excised in order to produce the mature 
rRNAs (Henras et al. 2015). The 5’ external transcribed sequence (ETS) segments, 
which located at +650 bp on 45S pre-rRNA in mouse and +414 bp in human, is 
processed out first. (Kass, Craig, and Sollner-Webb 1987; Kent, Lapik, and Pestov 
2009) Following its excision, the 5’ ETS fragment is rapidly degraded and the half life 
of this primary cleavage product is estimated to be only a few minutes in both mouse 
and human (Popov et al. 2013). The fast clearance of the 5’ETS segment enables the 
approximation of Pol I transcription rate by quantification of this sequence, for 
example by Northern blot or qRT-PCR.  
There are two potential targets for regulation of rRNA synthesis in response to the 
demand of cellular activities, the rate of Pol I transcription and the number of active 
rDNA genes. In general, not all the rDNA gene copies are continuously active 
(Conconi et al. 1989). French et al. has showed that a mutation yeast strain, which 
only have one third of the rRNA gene number but all active compared to the control, 
have similar grow rate as normal strain (French et al. 2003). They also suggested that 
this unaffected grow rate in mutation strain is likely due to the compensation by 
increased Pol I loading. This result suggested the important role for the regulation of 
rRNA synthesis by Pol I transcription in cell growth. 
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1.4.3 PIC factors and their functions 
As mentioned above, the initiation of rDNA transcription requires assembly of the 
pre-initiation complex (PIC) at the rDNA promoter, which containing Pol I and a 
large number of auxiliary proteins. Each of these proteins is under control of various 
regulatory pathways, which collectively form a tightly regulated structure for the 
RNA Pol I mediated rDNA transcription. 
TIFIA (Rrn3) 
RNA polymerase I forms a stable complex with the transcription initiation factor Rrn3 
through its subunit A43. (Milkereit and Tschochner 1998; Peyroche et al. 2000) Pol I 
subunit A49 also shows its contribution for the formation of the Pol I-Rrn3 complex 
and the subsequent dissociation. Functionally, TIFIA acts as a bridge for the other 
factors and facilitates their recruitment to the rDNA promoter. Once the transcription 
is initiated, TIFIA disassociates from the rDNA promoter region, unlike other factors, 
i.e. UBF, which remains bound (Milkereit and Tschochner 1998; Peyroche et al. 
2000; Aprikian, Moorefield, and Reeder 2001; Bier, Fath, and Tschochner 2004; 
Beckouet et al. 2008). 
UBF 
In mammals, two Pol I-specific factors, the upstream binding factor (UBF) and the 
promoter selectivity factor (SL1), bind to the rDNA promoter in a synergistic manner, 
initiating the assembly of the PIC complex (Jantzen et al. 1990; Learned et al. 1986; 
Moss et al. 2007). UBF belongs to a family of proteins that contain high mobility 
group (HMG) boxes. The HMG boxes enable UBF to loop approximately 140 bp of 
DNA into a single turn, thereby inducing a nucleosome-like structure, called 
enhanceosome (Bazett-Jones et al. 1994). UBF can activate the transcription of rDNA 
directly by recruiting Pol I to the rDNA promoter or indirectly by stabilizing the 
binding of TIF-IB/SL1 or displacing nonspecific DNA binding proteins such as 
histone H1 (Kuhn and Grummt 1992; Kuhn, Stefanovsky, and Grummt 1993). 
Besides these functions, other roles of UBF has been suggested which including 
regulation of Pol I promoter escape (Panov et al. 2006) and transcription elongation 
(Stefanovsky et al. 2006). Moreover, UBF likely displays a more important role as 
compared to other PIC factors due to the reason that the UBF-rDNA association is not 
only limited in the promoter region but also extends through the entire transcribed 
region. This may suggest that UBF binding could contribute open chromatin state of 
active rDNA (Chen, Belmont, and Huang 2004). Depletion of UBF leads to reversible 
methylation-independent silencing of rRNA gene and reduction in the number of 
actively transcribed rDNA repeats (Sanij et al. 2008). Both elevated UBF mRNA and 
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protein levels and increased UBF-rDNA binding have been reported during skeletal 
muscle hypertrophy, together with an increased rDNA transcription rate (von Walden 
et al. 2012). Therefore the role of mTOR as a modifier for the relative proportion of 
active and silent rRNA genes together with its role as part of PIC indicated the critical 
position of UBF in regulation of Pol I mediated transcription. 
The promoter of UBF gene contains an E-box motif (CACGTG), which can be 
recognized by the oncogene c-Myc and its heterodimers binding factor Max. c-Myc  
has been shown to regulate the UBF gene expression and hence indirectly enhance 
ribosome synthesis (Poortinga et al. 2004; Schlosser et al. 2003; Kim et al. 2000; 
Boon et al. 2001). We will further discuss the roles of c-Myc in section 1.4.4. 
SL1 
Pol I mediated transcription requires the TIF-IB/SL1 complex, a protein complex 
containing the TATA binding protein (TBP) and five TBP–associated factors, 
including TAFI110/95, TAFI68, TAFI48, TAFI35, and TAFI12 in mice (Zomerdijk et 
al. 1994; Heix et al. 1997; Gorski et al. 2007; Denissov et al. 2007). TAFI proteins 
undertake important functions in assembling of transcription complex, mediating 
specific interactions between the rDNA promoter and Pol I, and recruiting PIC 
together with Pol I to rDNA.  
PAF53 
Hanada et al. first reported the function of PAF53 in rRNA synthesis due to the 
correlation between the nucleolar accumulation of PAF53 and rDNA transcription. 
PAF53 is required for the initiation of rDNA transcription but likely not contributed to 
template binding elongation (Hanada et al. 1996).  
All these reports suggest a mechanism whereby RNA Pol I and PIC complex are 
recruited to the rDNA promoter together, which acts as a scaffold to coordinate rDNA 
transcription. 
1.4.4 c-Myc in regulation of ribosome biogenesis  
1.4.4.1 c-Myc 
One of the most studied groups of genes is the Myc oncogene family, comprising c-
Myc, N-Myc, L-Myc, B-Myc and S-Myc. Among all the family members, most of the 
functional studies have focused on the c-Myc. The human c-Myc was discovered in 
the beginning of the 1980s and the protein was originally discovered as the homolog 
v-gag-myc, present in myelocytomatosis virus (Lee and Reddy 1999; Meyer and Penn 
2008). Proper regulation of c-Myc expression is crucial for obtaining normal cell 
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functions. As it regulates the transcription of a wide range of genes, even small 
changes may influence cell growth, proliferation, apoptosis, differentiation and 
transformation (Meyer and Penn 2008; Levens 2010).  
The C-terminal part of c-Myc contains a basic helix-loop-helix-leucine zipper (bHLH-
LZ) motif, which interacts with the bHLHLZ motif of Max, forms a c-Myc/Max 
heterodimer. N-terminal to the HLH-LZ motif is the basic region (a.a. 355-369), 
which is involved in the c-Myc/Max binding to DNA but also necessary for full 
transformation of primary immortal cells (Meyer and Penn 2008). The c-Myc/Max 
heterodimer binds to specific DNA sequences (5´-CACGTG-3´) named enhancer 
boxes (E-box) (Blackwood et al. 1991; Nair and Burley 2003). Heterodimerization 
with Max is necessary for c-Myc DNA binding and cMyc is not able to form 
homodimers (Lavigne et al. 1998). 
1.4.4.2 Biological activities of c-Myc 
As a transcriptional factor, c-Myc can regulate a wide range of biological activities 
including but not limited to cell proliferation, cell growth, differentiation, 
transformation and apoptosis etc. Based on the global transcriptional analysis, 
approximately 15% of the genes in the human genome are under transcriptional 
regulation of c-Myc (Orian et al. 2003; Li et al. 2003). For example, c-Myc directly 
activates the transcription of Cyclin D and Cyclin E genes, which are important for 
cell cycle regulation (Mateyak, Obaya, and Sedivy 1999). Other genes involved in 
regulation of cell metabolism (LDHA) (Shim et al. 1997), apoptosis (Bcl-2) 
(Bissonnette et al. 1992) and miRNAs (Tao, Zhao, and Tao 2014) are also considered 
to be the direct targets of c-Myc. On the other hand, c-Myc lies downstream of many 
key-signaling pathways in cells. Wnt/ β-catenin signaling can upregulate c-Myc 
expression which promote the cell proliferation (Zhang et al. 2012). JNK and mTOR 
have also been shown to regulate c-Myc through the phosphorylation at Ser62. 
(Noguchi et al. 1999; Cianfanelli et al. 2015). Therefore, c-Myc acts as a critical role 
by integrating environmental signals to a diverse group of cellular processes in 
proliferating cells. 
1.4.4.3 c-Myc in ribosome biogenesis 
The regulation of ribosome biogenesis by c-Myc has been reported by several 
evidence, especially on the regulation of Pol I transcription (Arabi et al. 2005; 
Grandori et al. 2005; Grewal et al. 2005). Considering that c-Myc is able to directly 
regulate the expression of UBF, together with the fact that siRNA silence of UBF 
prevented c-Myc from fully activating rDNA transcription, it suggests that c-Myc can 
indirectly regulate rDNA transcription via UBF (Poortinga et al. 2004). It has also 
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been shown that the presence of c-Myc occurred together with the protein-protein 
interaction with SL-1 and increased acetylation of histones. Furthermore, c-Myc also 
binds to the promoter and downstream rDNA regions close to the transcription 
termination site, which indicates a potential direct regulatory role of c-Myc via gene 
looping in rapidly growing cells (Keppel 1986).  In the presence of c-Myc, serum 
stimulation rapidly leads to the formation of gene loop structures of rDNA, which 
may enhance the transcription rate (Shiue, Berkson, and Wright 2009). The regulation 
of Pol II and III dependent gene transcription has also been suggested in mammalian 
cells by c-Myc (Poortinga et al. 2011) and in Drosophila by the c-Myc homologue d-
Myc (Gomez-Roman et al. 2003; Grewal et al. 2005). Together, these findings 
suggested a crucial role of c-Myc in the regulation of efficient cell proliferation and 
ribosome biogenesis in single cells (Oskarsson and Trumpp 2005; van Riggelen, 
Yetil, and Felsher 2010).  
 
 
Fig. 2 The main cellular processes regulated by Myc together with some of the Myc 
regulated gene product. 
 
1.4.4.4 c-Myc in post mitotic cells 
A vast majority of the studies of c-Myc were conducted in a wide range of mitotic 
cells, i.e. different cancer-derived cell lines. It has been shown that c-Myc genomic 
deletion is lethal at embryonic day 10.5 (Davis et al. 1993). During embryogenesis, 
hematopoiesis has been suggested to be the crucial process, which interrupted by the 
absence of c-Myc and resulting in termination of embryo (Trumpp et al. 2001). 
Inhibition of c-Myc function severally impairs the growth-factor-induced proliferation 
 12 
of cells in culture(Roussel et al. 1996). These growth deficiencies may not only due to 
the crucial role of c-Myc in different cellular processes but also contributed by the 
connection between various cellular processes in eukaryotic cells. Failure or 
dysfunction of one key cellular activity (i.e. proliferation) will likely compromise 
other processes (i.e. cell growth) and eventually causes apoptosis. Therefore, by 
studying the mitotic cells, it is difficult to evaluate if c-Myc have a direct effect on one 
of the processes (i.e. Cell growth) as its broad role in other cellular processes.  
However, the level of c-Myc protein is generally low in post-mitotic cells (Armstrong 
and Esser 2005; Poortinga et al. 2011). c-Myc has been described to act a special role 
in the hepatocyte proliferation that occurs during liver regeneration (Fausto et al. 1986; 
Thompson et al. 1986). A reduction level of hepatic c-Myc does not affect normal 
postnatal liver growth and development. Furthermore, Sanders has shown that 
reducing c-Myc does not affect the restoration of liver mass during liver regeneration 
or the restoration of liver protein following fasting (Sanders et al. 2012). Together, 
these findings indicate that c-Myc may have a different regulatory function in post-
mitotic tissue comparing to proliferating cells. 
In skeletal muscle, increased localization of MyoD and Myogenin on the rDNA 
promoter has been reported to be correlated with the decreased c-Myc protein level as 
well as decreased rRNA synthesis rate during the lineage progression (Ali et al. 2008; 
Bowman 1987; Zahradka, Larson, and Sells 1991). c-Myc gene expression also 
decreases stepwise during post natal development (Veal and Jackson 1998; Whitelaw 
and Hesketh 1992). In skeletal muscle from adult mouse, both protein and mRNA 
level of c-Myc are barely detectable (von Walden et al. 2012). However, hypertrophic 
growth of skeletal muscle as a result of growth factor stimulation and increased 
loading re-induced c-Myc (Armstrong and Esser 2005; Endo and Nadal-Ginard 1986; 
Nakahara et al. 2003; Osbaldeston et al. 1993; von Walden et al. 2012). Furthermore, 
aged skeletal muscle has shown a decreased ability to re-induce c-Myc as compared to 
young muscle, which might considered to be one of the reasons for anabolic resistance 
(Alway 1997). All these data suggested that the role of c-Myc in skeletal muscle 
might various depending on the development stages.  
1.4.4.5 c-Myc in skeletal muscle glucose uptake 
Due to the physiological demands of the human body, blood glucose concentration 
must be regulated within a tight range (Abdul-Ghani, Tripathy, and DeFronzo 2006; 
Wasserman 2009). Glucose concentration might vary under different conditions in 
terms of feeding or exercise. Thus preventing substantial disturbance in blood glucose 
concentration becomes essential for human. 
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Skeletal muscle is considered as the primary site of postprandial glucose uptake (Katz 
et al. 1983; Ferrannini et al. 1985). The skeletal muscle glucose uptake includes three 
different processes. First, glucose need to be delivered to the muscle fiber, then 
transported across the plasma membrane and finally phosphorylated by hexokinase to 
irreversible utilized glucose inside the muscle fiber (Wasserman and Ayala 2005). 
Glucose transport is believed to be the rate-limiting step for skeletal muscle glucose 
uptake (Wasserman and Ayala 2005). A group of membrane proteins in charge of this 
process and in skeletal muscle the principle glucose transporter protein is GLUT4 
(Garvey et al. 1998; Goodyear et al. 1996). Considering the fact that c-Myc has been 
reported to regulate the genes for regulation of glycolysis (Kim et al. 2007) and 
several glucose transporter protein isoforms i.e. GLUT1 (Osthus et al. 2000), its 
potential role in regulation of skeletal muscle metabolism is yet to be revealed. 
1.4.5 mTOR in regulation of ribosome biogenesis 
The mechanistic target of rapamycin is a serine/threonine protein kinase, which 
belongs to the phosphoinositide 3-kinase-related kinases (PIKK) and is encoded by 
the mTOR gene in human (Harris and Lawrence 2003). It was discovered several 
decades ago that mTOR regulates cell growth, cell proliferation, protein synthesis, 
autophagy and transcription. Dysregulation or dysfunction of mTOR has been 
implicated as a contributing factor to several diseases (Jiang and Liu 2008). For 
example, disruption of mTOR leads to embryonic lethality at embryonic day 5.5 in 
mice (Gangloff et al. 2004; Murakami et al. 2004). Depending on which binding 
partners (like Raptor or Rictor) does mTOR associates with, two distinct complexes 
can form: mTOR complex 1 (mTORC1) or mTOR complex 2 (mTORC2). The 
mTORC1 pathway is believed to control many major processes via integrating inputs 
from several intracellular and extracellular resources like growth factors, stress, 
energy status and amino acids. On the other hand, it has been reported that mTORC2 
activation regulates cytoskeletal organization and cell survival (Laplante and Sabatini 
2012), however, the detailed function and regulation of mTORC2 required is less 
understood.  
1.4.5.1 The mTOR pathway 
The mTOR pathway is highly involved in the cellular response to nutrients by 
regulating ribosome biogenesis in response to amino acid availability. Downstream of 
mTOR, increased mTOR activity stimulates mRNA translation of protein and 
increased RNA transcription.  
mTORC1 phosphorylates the translational regulators eukaryotic translation initiation 
factor 4E (eIF4E)-binding protein 1 (4E-BP1) at several residues which promotes the 
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dissociation of eIF4E from 4E-BP1. This protein-protein disassembling consequently 
reduces the inhibitory effect of 4E-BP1 and leads to formation of eIF4F complex, 
which containing eIF4A/E/G. In the present of mTOR, eIF4F complex binds to 
specific structure of mRNA, therefore promotes mRNA translation. On the contrary, 
when mTOR level is low, 4E-BP1is hypophosphorylated and competitively binding to 
eIF4E and block translation initiation. Another subunit of the eukaryotic translation 
initiation factor, eIF4B, is believed to be a phosphorylation target of S6K1. 
Furthermore, mTOR phosphorylates (Brunn et al. 1997; Burnett et al. 1998) and 
thereby activates (Isotani et al. 1999) S6K1 (Thr 389), which in turn phosphorylates 
ribosomal protein S6 (rpS6). Besides rpS6 and eIF4B, the active S6K1 can also 
phosphorylates eukaryotic elongation factor 2 (eEF2) and thus promotes the 
translational elongation (Wang and Proud 2006). Therefore, by phosphorylates 4E-
BP1 and S6K1, mTOR can regulate protein synthesis in multiply levels. 
It has also been shown that mTOR regulates transcription by all three RNA 
polymerases through in several ways (Mayer and Grummt 2006). For the regulation of 
RNA Pol I mediated rDNA transcription, one of the functions of mTOR is that it 
regulates the activation/phosphorylation of PIC factors. Pol I was first reported to be 
rapamycin sensitive (Mahajan 1994). Thereafter, inhibition of the mTOR pathway 
was shown to result in inactivation of TIFIA by decreasing phosphorylation at serine 
44 (Ser44) and enhancing phosphorylation at serine 199 (Ser199) (Mayer et al. 2004), 
which suggests that balancing phosphorylations with opposite effects may play an 
important part of mTOR dependent regulation (Drygin, Rice, and Grummt 2010). 
mTOR was also shown to control the phosphorylation of the retinoblastoma protein 
RB to release UBF (Nader, McLoughlin, and Esser 2005). Furthermore, 
phosphorylation of UBF can be increased due to elevated mTOR signaling, thus 
promoting its interaction with SL1 (Hannan et al. 2003). The binding of the SL1 
complex to the rDNA promoter is also affected by mTOR following IGF-1 
stimulation (James and Zomerdijk 2004). On the other hand, by direct interaction with 
the promoter regions, mTOR regulates the 45S rDNA, 5S rDNA and tRNA in a serum 
dependent and rapamycin sensitive manner (Li et al. 2006; Tsang, Liu, and Zheng 
2010; Wei, Tsang, and Zheng 2009). mTOR phosphorylates and inhibits Maf1, a Pol 
III repressor, thereby inducing Pol III dependent 5S rRNA and tRNA transcription 
(Kantidakis et al. 2010).  
mTOR signaling is also involved in the post transcriptional regulation of pre-rRNA, 
generally termed as rRNA processing. Maturation of the 45S pre-rRNA requires 
several stages of splicing. It has been reported that mTOR regulate the processing of 
pre-RNA in yeast (Powers and Walter 1999) and in human (Iadevaia et al. 2012) cells, 
although the underlying mechanisms have not been fully understood. 
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1.4.5.2 mTOR and muscle growth 
mTOR is of great importance in all cell types. In skeletal muscle, phosphorylation of 
S6K1 was correlated with the increased muscle mass after resistance exercise (Baar 
and Esser 1999; Terzis et al. 2008). mTOR signaling was examined to be a crucial 
regulator of skeletal muscle mass as its regulatory function on protein synthesis 
(Anthony et al. 2000; Anthony, Anthony, and Layman 1999). Mechanical loading is 
sufficient to induce mTOR signaling (Goodman et al. 2011) and muscle hypertrophy 
was prevented when mTOR function was inhibited using rapamycin (Bodine, Stitt, et 
al. 2001). The activation of mTOR within skeletal muscle cells is sufficient to induce 
muscle hypertrophy (Goodman et al. 2011). Moreover, mTOR signaling can be 
induced by resistance exercise despite the absence of nutrition supply (Eliasson et al. 
2006; Apro et al. 2013; Dreyer et al. 2006). Due to these critical roles of mTOR 
pathway in skeletal muscle, this thesis further investigates the mechanism by which 
mTOR regulates ribosome biogenesis.  
1.5 PROTEIN DEGRADATION IN SKELETAL MUSCLE HYPERTROPHY 
In eukaryotic cells, there are two major pathways, the ubiquitin-proteasome system 
and autophagy-lysosome system, responsible for the degradation of most the cellular 
proteins. The ubiquitin-proteasome system (UPS) accounts for the degradation of 80-
90% of total proteins, which includes many regulated, short-lived proteins as well as 
abnormal or denatured proteins. On the contrary, autophagy is primarily responsible 
for the degradation of most long-lived proteins, but also for most of cellular organelles 
i.e. mitochondria, ribosomes. Both of these protein degradation pathways have been 
described to be activate in skeletal muscle under catabolic conditions (Bechet et al. 
2005; Tassa et al. 2003).  
1.5.1 Ubiquitin-Proteasome system 
To be recognized by the UPS, the target proteins need to be labeled with ubiquitin in 
advance. Ubiquitin (Ub), a 76 amino acids protein, can be assembled as an ubiquitin 
chain by multiple moieties of itself and then bind to the lysine residues on the target 
proteins as a degradation marker. In this process, Ub first needs to be activated by the 
action of a Ub activating enzyme (E1) and Ub conjugating enzyme (E2) then 
presented to the substrate protein, which is selectively targeted by the E3 ubiquitin 
ligases. More Ub will be added to establish a poly-ubiquitin structure. Afterwards, the 
poly-ubiquitinated proteins will be recognized by 19S proteasome complex then be 
cleaved by de-ubiquitinated enzymes (DUB) and eventually enter the 20S core for 
degradation. The final products, the constituting amino acids, will be recycled by cells 
as resource of protein synthesis. Ubiquitin could also be recycled and used for the next 
target protein. 
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1.5.1.1 UPS in atrophy 
Muscle atrophy occurs as the consequence of imbalance between anabolic and 
catabolic processes, when the rate of protein breakdown exceeds protein synthesis. 
Under many clinical conditions and chronic diseases, the loss of muscle mass may 
lead to muscle weakness or even increased mortality. It has been demonstrated almost 
50 years ago that an increase in protein degradation can contribute to the loss of 
muscle mass following denervation and glucocorticoid treatment (Goldberg 1969). 
After that, MAFbx/atrogin-1 and MuRF1, two muscle-specific Ub-ligases, were 
reported to be key regulators of muscle atrophy (Bodine, Latres, et al. 2001; Gomez-
Roman et al. 2003; Gomes et al. 2001). Both MuRF1 and MAFbx are maintained at 
low expression levels in resting skeletal muscle and can be rapidly increased due to a 
variety of stressors thus representing an early response to muscle loss in various 
species (Bodine and Baehr 2014). MuRF1 has been proven to degrade the myofibrillar 
proteins (Clarke et al. 2007) whereas MAFbx can target MyoD, a myogenic 
regulatory factor, to regulate the atrophy process. Moreover, the function of MuRF1 is 
also believed to control protein synthesis as elevated levels of protein synthesis has 
been reported in the MuRF1 knock out mice under certain atrophy conditions (Baehr, 
Furlow, and Bodine 2011; Koyama et al. 2008). 
Recently, researchers have suggested that the role of the UPS in muscle may also be 
important for both integrity and growth. When conditional knocked out one of the 
essential 26S proteasome protein in muscle, a significant deficit was shown in muscle 
growth and force generation (Kitajima et al. 2014). Resistance exercise has been 
shown to increase both protein synthesis and protein degradation in skeletal muscle 
(Rennie and Tipton 2000). The mRNA level of MuRF1 and MAFbx were also found 
increased within several hours following acute resistance exercise, which indicated an 
rapid increased ubiquitin proteasome-mediated proteolysis after resistance exercise 
(Murton, Constantin, and Greenhaff 2008). However, Baehr et al. (Baehr, Tunzi, and 
Bodine 2014) found that chronic loading of mouse skeletal muscle using the synergist 
ablation model induced skeletal muscle hypertrophy by increased protein synthesis 
and degradation through a MuRF1 independent UPS, which is in contrast to previous 
studies (Cunha et al. 2012). This controversial data suggested that the correlation 
between UPS and protein synthesis during hypertrophy has not been clearly 
understood, and the function(s) of the proteasome are more extensive than its 
previously suggested by its role in muscle atrophy. 
1.5.1.2 Transcription regulation of MuRF1 and MAFbx 
MuRF1 and MAFbx might be regulated by a similar sets of transcription factors due 
to the fact that they are transcriptionally up-regulated together under most atrophy-
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inducing conditions. The class O-type forkhead transcription factors (FOXO) is 
believed as the most potential transcriptional factor in regulation of MuRF1 and 
MAFbx. FOXO transcription factors (FOXO1, FOXO3a) have elevated expression 
level in skeletal muscle during certain forms of atrophy (Cho et al. 2010; Furuyama et 
al. 2003). It has also been reported that the activated FOXO1 can directly bind to the 
MuRF1 and MAFbx promoters (Waddell et al. 2008). Interestingly, FOXO1-promoter 
interaction was shown to be necessary but not sufficient to increase MuRF1 and 
MAFbx gene expression in cultured myotubes (Stitt et al. 2004). 
  
 
Fig. 3 Two major proteolytic pathways in skeletal muscle. A. Ubiquitin-proteasome 
system, B. Autophagy-lysosome system. 
 
 
1.5.2 Autophagy 
The autophagy-lysosome system degrades target proteins/organelles in a two-step 
process. The first step of autophagy is characterized ultra-structurally by the insolation 
of cytoplasmic constituents from the rest of cell into a double membrane-bound 
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vesicle called the autophagosome. Then the autophagosome subsequently fuses with 
the lysosome, leading to the degradation of its containing cytosolic proteins and 
organelles.  
Autophagy was originally identified as a form of programmed cell death and often 
believed as one of the mechanisms that cause muscle wasting (Sandri 2013). In both 
mice and human, autophagy is activated by endurance exercise due to its potential role 
in removal of proteins and organelles that are damaged during exercise (Grumati et al. 
2011). Autophagy has also shown a critical role in muscle adaptation and maintaince 
of healthy muscle. 
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2 AIMS 
The main aim of the work presented in this thesis was to understand the 
mechanisms regulating ribosome biogenesis in skeletal muscle hypertrophy. 
 
Objectives: 
1. Elucidate the changing of genes expression before and after chronic training 
as a response to an acute bout of RE. 
2.  Understand the alterations in catabolic and anabolic signaling during 
hypercapnia-induced atrophy. 
3. Determine whether c-Myc is necessary for skeletal muscle hypertrophy.   
4. Investigate the coordination between RNA polymerases in response to 
growth stimulus in skeletal muscle cells. 
5. Further investigate the function of mTOR in Pol I mediated transcription 
during muscle hypertrophy. 
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3 MATERIAL AND METHODS 
3.1 CELL CULTURE  
3.1.1 Culturing conditions for the C2C12 myogenic cell line 
C2C12 myoblast were grown to 90-100% confluence in growth medium (DMEM with 
10% FBS) and were induced to fuse into myotubes by being incubated in 
differentiation medium (DM: DMEM with 2% HS) for 4 days. To rid the terminally 
differentiated myotubes from undifferentiated myoblast, 20uM AraC was added to the 
medium for 24 hr on the third day after the induction of differentiation. Medium was 
changed every 2 days. At day 4 post differentiation, myoutubes were either 
maintained in DM or stimulated with high serum medium (GM: DMEM with 20% 
FBS) for 1, 3, 6, 12, 48h. All experiments were performed in a humidified 
environment at 37 in a 5% CO2 atmosphere. All the experiments were performed in 
triplicate.  
3.1.2 Chemical treatment  
Chemical inhibitors were used to block c-Myc function (Paper III) and PI3K, mTOR, 
p70S6K1, protein synthesis and Pol I and II (Paper IV). In Paper III c-Myc inhibition 
was accomplished using either Myra A (10-40 µM) (Mo and Henriksson 2006) or 
10058-F4 (60- 100 µM) depending on the experiment. PI3K, mTOR and p70S6K1 
inhibition was accomplished using LY294002 (20µM), rapamycin (25ng/ul) and PF-
4708671 (20µM, Pearce et al 2010), respectively. Protein synthesis was inhibited by 
cycloheximide treatment (10-50µM) and Pol I and II by CX-5461 1µM (Drygin et al 
2011) and DRB (75µM), respectively. DMSO was used as vector for all chemical 
inhibitors and the control group was supplemented with 0.1% DMSO. Medium was 
changed every day during stimulation.  
3.1.3 siRNA induced gene silence 
Paper III describes siRNA-mediated gene knockdown in C2C12 myoblasts. Cells were 
seeded in 6-well plates and transfected with c-Myc siRNA (50pM), Rrn3 (50pM) 
siRNA or control (50pM) siRNA. In Paper IV C2C12 myoblasts were seeded in 12-
well plates and double transfected at Day 3 and Day 5 post differentiation with 
p70S6K1 siRNA (50pM), rpS6 siRNA (50pM) or control siRNA (50pM). All siRNA 
products used were purchased from Santa Cruz and Lipofectamine 2000 (Invitrogen) 
was used as a transfection agent according to the manufacturers instructions. 
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3.1.4 Assessment of cell proliferation 
In Paper III, the effect of compromised c-Myc function on cell proliferation was 
assessed by two different approaches, 5-bromo-2'-deoxyuridine (BrdU)-incorporation 
assay detecting DNA synthesis and CFSE staining followed by fluorescence-activated 
cell sorting (FACS) to estimate number of cell divisions during a set period of time. 
For the BrdU-labeling assay myoblasts were grown on 8-chamber glass slides. After 
BrdU-incorporation, cells were washed with PBS followed by fixation in 15mM 
glycine-methanol solution for 20 min at - 20°C. Fixed cells were incubated with 
working solution for 30min, incubated with an anti- BrdU mouse antibody for 30 min 
and allowed to dry at room temperature, then covered with VectaShield Mounting 
Media containing 4,6-diamidino-2-phenylindole (DAPI). Visualization was performed 
using a multichannel Zeiss LSM-710 confocal microscope. For CFSE followed by 
FACS, myoblasts were labeled with 5µM CFSE for 10min at 37°C before plating and 
inhibitor treatment. After 48 or 72h samples were collected by trypsinization, labeled 
with Live/Dead cell dye (Invitrogen) for selection of viable cells only and run through 
a Gallios Flow Cytometer (Argon laser 488). Data analysis was performed using the 
Kaluza Analysis Software (Beckman Coulter, Brea, CA).  
3.2 ANIMAL MODELS AND SURGICAL PROCEDURES 
Generation of c-MycD/Dmice, animal husbandry, surgical procedures and tissue 
collection: To generate a conditional skeletal muscle c-Myc deletion, we crossed c-
Mycfl/fl mice (8) with MCK-Cre+/- mice (4). The F1 generation yielded Myc D/fl 
mice, which were then intercrossed to obtain the F2 generation that yielded 
conditionally deleted c-Myc mice (c-MycD/D). F2 mice were born at the expected 
Mendelian frequency, displayed normal perinatal morphology, growth rates and 
fertility. Prior to any data collection and/or experimentation the F2 generation was 
backcrossed onto the C57Bl/6J c-Myc fl/fl background for more than ten generations. 
Genotypes were verified in all mice by genomic PCR for MCK Cre, c-Myc floxed 
alleles and recombination at all breeding stages. Animals were kept on a 12:12-h 
light-dark cycle, had unlimited access to water, and were fed a standard rodent chow 
diet ad libitum.  
3.2.1 Synergist ablation model 
In Paper III a rapid and robust hypertrophic response was induced in the plantaris 
muscle by the synergist ablation model (Bodine and Baar 2012; Goldberg et al 1975). 
Functional overload was imposed by bilaterally removing soleii and gastrocnemii 
muscles. Control animals underwent a sham operation, where muscles were separated 
by blunt dissection, paying special attention to avoid any tissue damage. Animals 
were operated under surgical depth anesthesia, induced, and maintained with 
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Isofluorane (Baxter, Norfolk, UK). All procedures were approved by the local ethics 
committee and were carried out following Federation of Laboratory Animal Science 
Associations guidelines for animal experimentation (FELASA).  
3.2.2 Glucose tolerance test 
Mice were fasted for 6h by transferring mice to clean cages with no food or faeces in 
bottom of the cage but with the access to drinking water at all times. Body weights 
were measured and the volume of IP glucose injection (ul) was calculated as 10 x 
body weight (g) as in 30% glucose solution. Baseline glucose level was measured 
once upon removed the tip of tail following by an intra-peritoneal injection with the 
appropriate amount of glucose solution. The blood glucose levels were further 
measured at 15, 30, 60 and 120 minutes by placing a small drop of blood on a new test 
strip and recording the measurement. 
3.2.3 Single fiber preparation 
To minimize the influence of non-muscle cells on assessment of degree of 
recombination, single muscle fibers were isolated and used for PCR (Paper III). 
Flexor digitorum brevis (FDB) muscles were cleaned of connective tissue, fat and 
blood vessels under a dissecting microscope using a pair of micro-iris scissors and 
jeweller’s forceps. The clean FDB muscles were incubated for 2-3 hours at 37 ºC in 
0.3% Type I collagenase in DMEM supplemented with 10% FBS. Next, the muscles 
were transferred to fresh DMEM at 37 ºC and gently triturated to produce a 
suspension of single muscle fibers. 300 µl of the resultant muscle fiber suspension 
was then placed in laminin coated glass-bottom Petri dishes and fibers were allowed 
to attach for 15 minutes before 2.7 ml DMEM supplemented with antibiotic, 
antimycotic solution (1 µL/ml) was added. Dishes containing muscle fibers were 
cultured for up to 48 hours at 37 ºC. 
3.2.4 Tissue collection 
In Paper III mouse muscles were collected from live animals under surgical anesthesia 
induced and maintained by isoflurane. Excised muscles were cleaned of non-muscle 
tissue, blotted to remove blood and weighed on a precision scale (Sartorius Acculab 
ATL-84, Göttingen, Germany). Muscles were then snap frozen in liquid nitrogen, or 
mounted for histochemistry in OCT mounting medium and frozen in liquid nitrogen 
cooled isopentane. Following dissections, animals were euthanized by cervical 
dislocation.  
In Paper I, muscle samples were collected bilaterally from the m. Biceps brachi using 
the Bergström needle biopsy technique (Bergstrom 1962). In order to facilitate sample 
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collection, suction was applied to the needle. Muscle biopsies were cleaned from 
visible fat and connective tissue, dry blotted and snap frozen in liquid nitrogen.  
All samples were stored at -80°C until subsequent analysis.  
3.3 HUMAN SUBJECTS AND RESISTANCE EXERCISE 
In Paper I, 13 human subjects (six women and 7 men, mean age 24 ± 1.4 years) 
participated. None of the subjects had prior RE training history, were not diagnosed 
with a chronic disease and were dietary supplement- and medication-free. All subjects 
maintained their normal dietary habits during the study. All participants gave their 
informed written consent to participate, and the local ethical committee approved all 
procedures.  
3.3.1 Group designation  
Subjects were randomly allocated to one of two groups, the training+acute (T+A) or 
acute (A) group. Both groups trained the non-dominant (ND) arm for 12w and 
performed an acute bout of RE 7 days after the last training session, but differed with 
respect to treatment for the dominant (D) arm. T+A used the D arm as a non-exercise 
control and A performed the same acute bout of RE as described for the ND arm. 
Considering the aim of investigating acute gene expression before and after 12 weeks 
of RE training, we designated the D arms of those in the T+A group as control (i.e., 
no exercise), the D of the A group as acute RE, and the ND arm of both groups as 
training+acute RE.  
3.3.2 RE training and dynamic strength testing  
RE training consisted of a supervised, 12w progressive weight-lifting program of the 
upper arm 2 days per week as previously describe (Gordon et al. 2012). In short, 
upper arm exercises (biceps preacher curl, biceps concentration curl, standing biceps 
curl, overhead triceps extension, and triceps kickback) were performed for three sets 
using the six repetition maximum (RM) weight. Two min rest was allowed between 
sets. Prior to and after (48-72h after last training session) the 12w training program, 
dynamic strength was tested using the 1 RM weight for the elbow flexors (preacher 
curl). Two warm-up sets were completed at 50% and 75% of the predicted 1 RM for 8 
repetitions and 5 repetitions, respectively. Single attempts were performed until one 
single repetition with full range of motion was completed. Dynamic strength gain was 
determined by calculating the percent difference between post- training and pre-
training 1 RM strength.  
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3.3.3 Muscle CSA measurements  
Magnetic resonance imaging (MRI) was used to observe changes in whole muscle 
cross- sectional area (CSA). Pre-training MRI scans were performed before or 48h 
after 1 RM testing and post-training MRIs were performed 48–96h after the last 
training session. To ensure precise and reliable measurements, six slices from each 
image were analyzed using bone morphological landmarks to ensure the same regions 
were measured pre- and post- training. Once the region of interest was segmented, 
total volume was determined for the six evaluated slices. Repeatability and reliability 
of Rapidia® volume measurements were verified using a phantom of known volume.  
3.4 MATERIALS 
C2C12 myoblasts were from American Type Culture Collection (Manassas, VA, 
USA). All chemicals were purchased from Sigma (Sigma-Aldrich, St.Louis, MO, 
USA) unless otherwise stated. Horse serum (HS) was purchased from GIBCO (Grand 
Island, NY, USA). Laemmli buffer and DC Protein assay were obtained from Bio-Rad 
Laboratories (Hercules, CA, USA). TRIzol, Superscript VILO cDNA synthesis kit, 
Lipofectamine 2000, Carboxyfluorescein diacetate succinimidyl ester (CFSE) and 
Live/Dead cell dye were from Invitrogen (Invitrogen, Carlsbad, CA, USA). Complete 
Mini protease inhibitor cocktail and PhoStop phosphatase inhibitor were from Roche 
Diagnostics (Indianapolis, IN, USA). All siRNA oligos were purchased from Santa 
Cruz Biotechnology (Santa Cruz, CA, USA). Primary antibodies used for 
Immunoblotting were from Santa Cruz Biotechnology, Cell Signaling (Beverly, MA, 
USA) or Abcam (Cambridge, UK).  
3.5 PROTEIN ANALYSIS 
In Paper I and III mouse and human muscle was homogenized in 
radioimmunoprecipitation assay (RIPA) buffer by use of a 5-mm generator coupled to 
a polytron (Kinematica, Kriens, Switzerland). In Paper IV cells were lysed in a 4-(2- 
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES)-based lysis buffer. The lysis 
buffer was supplemented with protease and phosphatase inhibitors. Following 
additional passive lysis at +4°C on a rotating wheel, lysates were spun down at 12,000 
x g to pellet insoluble material. Supernatants were collected and protein 
concentrations assessed by the DC Protein Assay (Biorad, Hercules, California, USA). 
Protein homogenates were diluted with lysis buffer if needed and mixed 1:1 or 3:1 
with 2X or 4X Laemmli buffer containing 5-10% β-mercaptoethanol. Samples were 
boiled at 95°C for 10 min and immediately cooled on ice and stored at -20°C until 
further use. Samples were separated by SDS-page on 7.5-12.5% polyacrylamide gels 
(Paper III) or precast Biorad gradient gels (4-20%) (Paper II and IV), depending on 
the size of the protein studied, and transferred to polyvinylidene difluoride (PVDF) 
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membranes activated in 100% methanol. Western blotting was performed using 
standard techniques: membranes were blocked in a protein-containing buffer, and 
washes were performed with Tris buffered saline- Tween 0.1% (TBS-T). Primary 
antibodies used were as follows: Paper I, rpS6 and PO4-rpS6 Ser235/236(1:1000, Cell 
Signaling) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH, 1:1000, Santa 
Cruz Biotechnology). Paper III, c-Myc (1: 1000, Abcam), c-Myc (1:500, Santa Cruz 
Biotechnology), RRN3 (1:1000, Abcam) and GAPDH (1:1000; Santa Cruz 
Biotechnology). Paper IV, mTOR, PO4-mTOR Ser2448, p70S6k1, PO4-P70S6k1 
Thr389, rpS6, PO4-rpS6 Ser235/236, PDCD4 (1:1000, Cell signaling) and GAPDH 
(1:1000, Santa Cruz Biotechnology). All primary antibodies were diluted in a TBS-
based buffer supplemented with 1% NaN3 and 1% bovine serum albumin (BSA). 
Secondary antibodies (Anti-rabbit 1: 5000; GE Healthcare) were diluted in 5% milk in 
TBS-T.  
3.6 PROTEIN SYNTHESIS MEASUREMENT 
Myotubes grown in 6-well plates were maintained in DM, or stimulated with GM, 
GM + 25ng/ml Rapamycin or GM + 1µM CX-5461 for 24h after which cells were 
washed once with PBS and incubated in media containing 35S- labeled methionine 
(40µCi) for 90min. Thereafter media was collected from each individual well as 
reference and cells were washed three times in cold PBS and lysed in cell lysis buffer. 
Lysates were spun down 5 min at 12000xg to pellet insoluble debris and supernatants 
transferred to new tubes. Lysates (15µl) were used to determine protein content using 
the DC protein assay (Biorad). Protein was then precipitated using TCA to quantify 
35S-incorporation. TCA precipitates were washed in Acetone-HCl (10%) and 
resuspended in elution buffer (100mM NaOH 1% SDS) at +55°C. 35S incorporation 
was measured on a Wallac scintillation beta counter. Counts per minute (CPM) from 
protein samples were normalized to protein content (µg), incubation time and specific 
activity of the media for each well (CPM) using the following formula: Protein 
synthesis rate=((CPM (protein pellet)/protein in well (mg))/incubation time (h))/CPM 
(media). 
3.7 HISTOCHEMISTRY 
Myotubes were grown on the 4 well chamber slides. After stimulation with GM, cells 
were washed with Phosphate buffered saline (PBS) twice followed by 4% PFA for 
20min. Then cells were permeabilized by PBS-T (0.1% Tween) for 10min, and 
washes were performed with PBS. Cells were blocked in 5% Goat serum in PBS-T. 
Primary antibodies were diluted (MHC, 1: 100) in blocking buffer and incubated with 
cells overnight. Secondary antibodies were diluted (1:200) in PBS. After three 
washes, VESTA SHIELD mounting Medium with DAPI was used for mounting. 
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Visualization was performed using a multichannel Zeiss LSM-710 confocal 
microscope.  
3.8 RNA ANALYSIS 
For total RNA extraction cells were collected in TRizol Reagent (Invitrogen) and 
subsequently extracted using Direct zol columns (Zymo Research). RNA purity and 
quantity were analyzed using a Nanodrop apparatus (xxx) and RNA integrity and 
column RNA size cutoff was verified by agarose gel electrophoresis. RNA was stored 
at -80°C until further use. cDNA was synthesized from 1µg of total RNA by the 
VILO cDNA synthesis kit accordingly to the manufacturer’s recommendations. The 
cDNA stock was further diluted for downstream Quantitative Real-Time Polymerase 
chain reaction (qRT-PCR) depending on the target gene. qRT-PCR was performed 
using a SYBR-chemistry based supermix (GoTaq, Promega) on the BioRad CFX 384 
system. Reactions were run in triplicate for each sample on 384 well, white hard-shell, 
clear well plates. Primers were tested on a 64-54°C heat gradient in order to optimize 
annealing temperature and verify a primer efficiency of approx. 100%. A melt-curve 
analysis was performed for each primer pair to ensure the amplification of a sole PCR 
product and amplicon size was verified by agarose-gel electrophoresis. 
3.9 CHROMATIN IMMUNOPRECIPITATION 
Chromatin Immunoprecipitation was performed on C2C12 myotubes and myoblasts 
(Paper III and IV) to assess protein association to promoter regions of interest. Sham 
and overloaded plantaris muscles were finely minced in a HEPES-based crosslinking 
buffer into a muscle slurry and cross-linked for 30 min in 1% formaldehyde. 
Myoblasts and myotubes were cross-linked by addition of formaldehyde directly to 
the cell culture media at a final concentration of 1%. The cross-linking reaction was 
quenched by the addition of glycine. Cells were collected in PBS and spun down at 
1400 rotations per minute (rpm) for 5 min at +4°C. After removal of PBS, cells were 
lysed in ice- cold FA lysis buffer. Chromatin was sheered to produce DNA fragments 
of approximately 500-1500bp. Cross-linked and sonicated homogenates were stored 
at -80°C until further use. Sample DNA concentration was assessed using heat de-
cross-linking overnight, proteinase K treatment and subsequent glycogen assisted 
precipitation of DNA following phenol/chloroform separation. The air-dried DNA 
pellet was diluted in RNase/DNase/nucleotide free H2O and rehydrated for 1h at 
+65°C. DNA was quantified by Nanodrop at 260nm. 5-10µg of DNA was used per 
immunoprecipitation (IP) reaction. Samples were diluted to a final volume of 500µl. 
2-3µg of antibody was added to each reaction and samples incubated overnight at 
+4°C on a rotating wheel. Magnetic beads were blocked over-night in a blocking 
buffer (glycogen, BSA and salmon sperm) and washed before diluted in IP dilution 
 28 
buffer. 50µl of pre-blocked beads were added per reaction and samples incubated 60 
min at room temperature. Beads were pulled down using a magnetic stand and washed 
several times. 150µl of elution buffer (1% SDS, 100mM NAHCO3) was added to 
each tube and quickly spun down before heated at +30°C for 15 min. Eluted antibody- 
protein-DNA complexes were de-cross-linked, proteinase K digested and the DNA 
extracted as described above for input DNA concentrations. Samples were quantified 
using qPCR with primers specific for the rDNA promoter. Normalization was 
accomplished by normalization to rDNA signal of IgG control or to a non-related 
genomic region, respectively, and expressed as fold enrichment.  
3.10 STATISTICAL ANALYSIS 
Paper I  
Differences in strength and CSA were compared using a two-way ANOVA with 
factors gender and training status followed by the Bonferroni post hoc test 
(significance level set at P < 0.05). Data are reported as mean ± SE. Differences 
between groups for qRT-PCR data and Western blotting were determined using a one- 
way ANOVA, and significance between groups was established using the Newman-
Keuls multiple comparison test (P < 0.05). All gene expression values are reported as 
means ± SE.  
Paper II 
Data are expressed as mean ± SEM. When comparisons were performed between two 
groups, significance was evaluated by the Student t test, and when more than two 
groups were compared, ANOVA was used followed by the Dunnett test, using 
GraphPad Prism software. Results were considered significant when p<0.05.  
Paper III  
Data was analyzed by the Student T-test, one- or two-way ANOVA followed by 
Newman- Keuls or Bonferroni post hoc test depending on the experiment. The level 
of significance was set at P< 0.05 for all statistical comparisons. Values are reported 
as means ± SD.  
Paper IV  
Differences between groups for total RNA, total protein, myotube diameter, gene 
expression and Western blot data were determined using the Student T-test or a one-
way analysis of variance (ANOVA) followed by the Newman-Keuls post hoc test (if 
more than 2 groups were involved). Ch-IP data was analyzed independently per time 
point using one-way ANOVA followed by the Newman-Keuls post hoc test. The level 
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of significance was set at P < 0.05 for all statistical comparisons. Values are reported 
as mean ± standard deviation (SD), unless stated otherwise.  
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4 RESULTS AND DISCUSSION 
4.1 PAPER I 
There are several reports showing that skeletal muscle adapts to chronic exercise due 
to a step-wise accumulation of different proteins and gain of function after repeated 
bouts. It has been widely studied on the gene expressions following the training. 
However, there is a lack of systematic profile on the expression patterns of a selected 
group of genes and little is known about the molecular mechanism underneath the RE 
training-induced adaptations. For example, genes involved in immune responses are 
attenuated following a short-term RE training as well as other genes responded in an 
opposite pattern (Gordon et al. 2012). One theoretically hypothesis is that following 
each exercise bout, an acute transcriptional response of higher magnitude occurs than 
that following the successive bouts.  (Bickel et al. 2005). Thus this study investigates 
the acute response of four focused gene groups, which are all involved in skeletal 
muscle RE adaptation, to acute exercise in naïve and trained skeletal muscle. 
13 untrained subjects underwent supervised RE training for 12 week of the non-
dominant arm and performed an acute bout of RE 1 week after the last bout of the 
training program (Training + Acute). The dominant arm was either unexercised 
(control) or subjected to the same acute exercise bout as the trained arm (acute RE). 
By designing the subjects in this way, we have the chance to evaluate the differences 
between gene expressions in three different exercise stages – resting, acute exercise 
and acute exercise in the trained state (12 week training). 
Twelve weeks of RE training resulted in morphological adaptations reflected as 
increased muscle CSA. Dynamic strength was also increased as an indication of 
muscle functional adaptation. Consistent with previous studies, an increased 
phosphorylation level of rpS6 ser235/236 was observed after acute RE. However, 
following 12 week of RE training, the increased phosphorylation of rpS6 was 
attenuated. Compared to reports on altered mTOR signaling during by chronic 
resistance training (Ogasawara et al. 2013) and reduced protein synthesis in response 
to anabolic stimuli in trained skeletal muscle (Phillips et al. 1999), this reduction on 
rpS6 phosphorylation in training +acute to acute RE muscle may revealed the 
molecular mechanism behind RE training-induced adaptations. 
We also focused on the ability of anabolic regulation after RE. It has been shown that 
the rate of protein synthesis rate is proportional to muscle RNA contents. Together 
with the fact that RNA Pol I mediated rDNA transcription is the rate limiting step for 
ribosome biogenesis, we found that pre-rRNA levels (ETS) increased two fold after 
acute RE. As one of the rDNA transcription regulators, c-Myc was also found a 
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remarkable increase after acute RE. This evidence supports the previous findings on 
ribosome biogenesis in response to acute mechanical loading across mammalian 
species. Consistence with decreased anabolic signaling i.e. attenuated phosphorylation 
of rpS6 in training+ acute group, both ETS and c-Myc were found reduced in 
response to acute RE following 12 week of RE training compared to acute RE. 
Furthermore, we also found that following 12 week of RE training, changes in gene 
expression are multidimensional, as not all the genes responded to acute RE and the 
responses could be either enhanced or suppresses following training state. Therefore, 
the correlation between the changing of gene expression profile and developing 
muscle phenotype is likely depending on the gene function.  
In summary, this paper provides novel data indicating that changes in gene 
expressions following acute RE are multidimensional, and do not necessarily reflect 
the actual adaptive response that taking place during the training process.  
4.2 PAPER II 
Loss of skeletal muscle mass and/or muscle dysfunction is a common feature in aging 
and some diseases, e.g. chronic obstructive pulmonary disease (COPD). For the 
COPD patients, due to a disturbance in pulmonary gas exchange, both transportation 
of CO2 from muscle and transportation of O2 to muscle are impaired. It has been 
shown that high CO2 levels can activate signaling pathways that impair the innate 
immune response or the functions of other organs (Wang et al. 2010; Helenius et al. 
2009; Gates et al. 2013). However whether this CO2 retention (hypercapnia) induces 
skeletal muscle atrophy is still yet to be answered. Thus this study investigated the 
activation of the proteolytic systems and suppression of the anabolic systems in 
hypercapnia induced skeletal muscle atrophy. 
To investigate whether hypercapnia can causes skeletal muscle atrophy, mice were 
exposed to 10% CO2 and 21% O2 (hypercapnia) or to room air (normocapnia). The 
wet weight of the soleus muscle under hypercapnia was 10% less as compared under 
normocapnia. Both muscle cross-section area and strength were also found decreased 
in mice exposed to hypercapnia. As decreases in protein content, muscle fiber 
diameter and force production are the basic evaluation factors of skeletal muscle 
atrophy, our data in mice were similar to those observed in hypercapnic patients with 
COPD (Dick et al. 1997). To further confirm this hypercapnia induced atrophy 
phenotype, we addressed this phenomenon using the in vitro C2C12 myogenic cell line. 
Increased level of CO2 caused thinner myotubes and lower protein contents in 
consistent with our in vivo results. 
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During muscle atrophy, proteolytic systems are activated and contribute to wasting of 
muscle fibers. To investigate the involvement of the ubiquitin proteasome system in 
the hypercapnia induced atrophy, proteasome inhibitor MG-132 and the ubiquitin-
conjugating enzyme inhibitor UBE were applied to treat with mature myotubes. 
Inhibition of UPS prevented the hypercapnia-induced reduction in myotubes diameter. 
Considering that the specificity of the UPS is carried out by ubiquitin ligases E3, we 
further investigated the function of muscle-specific Muscle Ring Finger-1 (MuRF1) 
during hypercapnia. The protein and mRNA level of MuRF1 is upregulated following 
hypercapnia, and suppression ofMuRF1 by siRNA had a protective effect against the 
hypercapnia induced atrophy. To further validate these findings, MuRF1 knock out 
mice were exposed to high CO2 for 21 days. Consistent with our previous findings, 
absence of MuRF1 in muscle prevented the hypercapnia-induced reduction in both 
morphology and strength.  
AMPK has been shown to mediate skeletal muscle protein degradation via atrogin-1 
and MuRF1 (Nakashima and Yakabe 2007). Furthermore, acetyl-CoA carboxylase 
(ACC) phosphorylation of AMPK and nuclear FoxO3 showed increased patterns 
compared to MuRF1 when myotubes were treated with high CO2. siRNA interference 
with different AMPK subunits or FoxO3 suggested that AMPKa2 and FoxO3 were 
necessary for CO2 induced decrease in myotubes diameter and indicated that 
hypercapnia causes muscle atrophy via AMPK-FoxO3-MuRF1 signaling pathway.  
In summary, hypercapnia-induced atrophy required increased catabolic signaling 
pathways such as AMPK-FoxO3-MuRF1 as well as decreased anabolic signaling 
exemplified by rDNA transcription. This finding indicated that in the dynamic process 
of protein modification, coordination of protein synthesis and degradation is of great 
importance. 
4.3 PAPER III 
The upregulation of c-Myc and 45S pre-rRNA induced by acute RE in skeletal muscle 
has been studied in Paper I. Among many functions of c-Myc, the regulation of 
ribosome biogenesis is a key factor for cellular growth control. While c-Myc is 
relatively well characterized in proliferating cells, little is known about the role of c-
Myc in post-mitotic tissues, i.e. skeletal muscle. To understand the role of c-Myc in 
skeletal muscle and in transcriptional regulation of RNA Pol I/II/III, we started from 
the test of whether c-Myc is necessary for post-natal skeletal muscle development and 
hypertrophy following increased load. 
Using the Cre-LoxP system, we generated a transgenic mouse model, in which c-Myc 
is specifically knocked out in mature skeletal muscle fiber. To avoid the effect of c-
  33 
Myc depletion during the developmental stage (Trumpp et al. 2001), we chose the 
muscle creatine kinase promoter (MCK) to drive Cre, because MCK is only expressed 
in mature skeletal muscle fibers. This mouse model helps us to investigate the effect 
of c-Myc in post-mitotic myofibers, instead of myogenesis.  
From post-natal development throughout adult age (up to 48 week), no differences 
were detected between genotypes in terms of body weight, perinatal mortality or 
developmental defects. Skeletal muscle mass were examined by the wet weight of 
Plantaris, Tibialis anterior or Extensor digitorum longus and cross-section area of 
plantaris muscle. Surprisingly, no morphological changes were observed in c-Myc 
conditional knock out mice compared to control. Despite a significant reduction in c-
Myc mRNA levels up to 12 week, the absence of c-Myc did not affect basal 
transcription of 45S rDNA by Pol I or 5S rDNA by Pol III. The gene expression level 
of several PIC factors, also known as c-Myc targeted genes, displayed a similar 
pattern compared to control. Although these results contradict our initial hypothesis 
that absence of c-Myc would prevent muscle growth by limiting foremost rDNA 
transcription and thereby ribosome production, these novel findings indicate that c-
Myc is dispensable for rDNA transcription and post-natal skeletal muscle 
development.  
To challenge the role of c-Myc during rapid growth following mechanical overload, 
we used a rodent model of skeletal muscle hypertrophy, synergist ablation of plantar 
flexor muscles (Goldberg et al. 1975). Gastrocnemius and Soleus were removed 
bilaterally resulting in increased mechanical loading of the remaining Plantaris. To 
avoid the influence of other tissue responses/activities i.e. inflammatory activity, other 
than the increased loading on skeletal muscle, we performed a bilateral sham 
operation on the control group animals, including skin and fascia incisions, 
manipulation of muscles and exposure of tendons but no removal of muscles (von 
Walden et al. 2012). Compared to the barely detectable expression level of c-Myc in 
adult skeletal muscle, c-Myc increased dramatically but much less of increase in the c-
Myc conditional knock out mice. One of the potential explanations for the observation 
that c-Myc was detectable in c-Myc conditional knock out mice could be contribution 
by non-muscle cells. Skeletal muscle in lack of c-Myc displayed a similar response to 
mechanical overload when compared to control i.e. similar muscle mass increase, 
RNA content increase and more portions of large fibers. Thus, work-induced 
hypertrophy did not necessitate c-Myc, which indicates that unlike in cardiac muscle, 
where c-Myc is necessary, c-Myc is dispensable for adult skeletal hypertrophy. 
Due to the possibility that genetic deletion of c-Myc was compensated by other 
factors during post-natal development, we further investigated the function of c-Myc 
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in vitro cell culture system (C2C12 myotube and myoblast). Mature myotube was 
differentiated and fused from single nucleated proliferating myoblast. By using a c-
Myc inhibitor, Myra A, to prevent c-Myc interaction with DNA, mature Myotube did 
not show any defect on protein or RNA accumulation after 48h of drug administration. 
Consistent with the response of rRNA to overload in c-Myc conditional knock out 
mice, rDNA transcription and gene expression level of c-Myc were not affected either. 
These results reinforced the conclusion that the function of c-Myc is dispensable for 
post-mitotic skeletal muscle hypertrophy.  
However, in proliferating cells, c-Myc plays a different role in ribosome biogenesis. It 
has been shown that c-Myc is essential for embryonic development. Low level of c-
Myc during embryogenesis results in dwarfism due to reduced cell number rather than 
cell size. In myogenic cell line, c-Myc inhibits myogenic differentiation, which 
suggests a potential cell-stage-specific c-Myc function. To prove the different roles of 
c-Myc in proliferating cells and post-mitotic cells, we carried out experiments in an 
undifferentiated myogenic context using C2C12 myoblasts, where c-Myc was either 
ablated by siRNA or functionally blocked by inhibitors. Silencing of c-Myc 
expression with siRNA reduced cellular proliferation rates and reduced rDNA 
transcription. Compared to the result from silencing a well-established Pol I 
transcription factor RRN3, it is highly possible that the reduced proliferation rate is 
due to the effect of lack of c-Myc on regulation of rRNA synthesis. By using Myra-A 
in myoblast, reduced ribosome biogenesis and cell growth were further confirmed due 
to the lack of c-Myc function.  
In summary, this paper suggested a cell stage specific role of c-Myc in ribosome 
biogenesis, which is essential for proliferating cells but not for post-mitotic cells. 
4.4 PAPER IV 
mTOR is essential for de novo rRNA synthesis. Pol I dependent 45S rDNA 
transcription is believed to be the rate limiting step of ribosome biogenesis. It has been 
shown that rDNA transcription is an early event during skeletal muscle hypertrophy. 
This study focused on the effect of mTOR on rDNA transcription and the importance 
of rDNA transcription during muscle hypertrophy.  
High serum stimulation of mature C2C12 myotube resulted in increased protein content, 
RNA content and thicker myotubes. Consistent with previous publications, rRNA 
content is proportional correlated with protein synthesis rate, as rDNA transcription 
has an early response to high serum (Millward et al. 1973). Increased 
phosphorylations of mTOR/S6K1/rpS6 were observed after serum stimulation, which 
further confirmed the involvement of mTOR pathway during skeletal muscle 
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hypertrophy. To further investigate the mechanism, we used biochemical inhibitors to 
target different signaling molecules along the mTOR pathway, respectively, during 
high serum stimulation. We found that dysfunction of PI3K or mTOR but not S6K1 
prevented the transcription of rDNA. S6K1 RNA interfering experiment showed 
similar results, which suggested that S6K1 inhibition do not affect transcription. One 
explanation is that S6K2 may compensate the absence of S6K1, as it has been 
indicated in the other cell types (McMullen et al. 2004). 
Inhibition of mTOR suppressed protein synthesis rates and rDNA transcription rate. 
To distinguish these two processes and their regulatory effect on rDNA transcription, 
we applied CHX and DRB to block protein synthesis and Pol II transcription 
respectively. CHX showed a strong effect on suppressing rDNA transcription, which 
possibly due to the depletion of essential PIC factors. It also indicates that the activity 
of Pol I transcription requires a protein synthesis rate that above the resting level. 
DRB treatment showed a clear evidence that Pol II transcription was prevented during 
hypertrophy, which produced an imbalance between 45S pre-rRNA ETS and ITS. 
These data suggest an important role of Pol II transcription in Pol I elongation more 
than initiation. The expression of PIC factors showed different patterns between CHX 
and DRB, which indicates the function of mTOR signaling on protein synthesis may 
be distinct from its regulatory function to Pol II transcription. All these results suggest 
that mTOR signaling probably indirectly controls Pol I transcription by regulating Pol 
II mediated gene transcription. 
To further understand the role of mTOR in directly regulation of Pol I transcription, 
we applied CX-5461, a selective Pol I inhibitor, in serum-stimulated myotubes and 
compared with Rapamycin. CX-5461 prevented the elevation of rDNA transcription 
to a similar level compared with rapamycin and inhibited hypertrophy. Furthermore, 
CX-5461 did not negatively affect Pol II genes. Interestingly, blockage of Pol I by 
CX-5461 also prevented the increase in protein synthesis, which suggests a regulatory 
function of Pol I transcription on protein regulation. These results indicate a necessity 
of de novo rRNA synthesis for skeletal muscle hypertrophy. In addition, we observed 
increased association of mTOR with the rDNA promoter following serum stimulation 
in a Rapamycin sensitive matter. However, Rapamycin did not affect the nuclear 
exclusion of mTOR, which suggests that there is a nuclear fraction of the mTOR pool 
regardless of its DNA binding activity at the rDNA promoter. Therefore, nuclear 
mTOR signaling might provide a mechanism for regulation of gene expression and 
Pol I transcription independent of cytoplasmic mTOR.  
In conclusion, we confirmed previous findings that mTOR signaling plays an 
important and coordinating role in protein synthesis and ribosome biogenesis. Our 
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data also indicates that during muscle hypertrophy, an increase in Pol I-dependent 
rDNA transcription is necessary for protein synthesis, and enhanced ribosome 
production. 
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5 CONCLUSIONS 
 
Acute resistance exercise training stimulates Pol I transcription. Gene expression 
following training is highly sensitive to the training state, and does not reflect the 
actual adaptive processes. (Paper I) 
Anabolic capacity as ribosome biogenesis in muscle cells is attenuated by hypercapnia 
due to regulation of MuRF1 expression and muscle catabolism. (Paper II) 
c-Myc gene expression is induced following mechanical loading in mouse and human. 
However, c-Myc is dispensable for post-natal skeletal muscle development, work-
induced skeletal muscle hypertrophy and Pol I/II/III transcription. (Paper III) 
Dysfunction of c-Myc in mitotic cells impairs Pol I transcription and reduces cell 
proliferation compared to the dispensable role of c-Myc in post-mitotic cells during 
C2C12 myotube hypertrophy. (Paper III) 
Pol I dependent rDNA transcription is necessary for protein synthesis and C2C12 
myotube hypertrophy. (Paper IV) 
The regulation of mTOR on Pol I transcription does not depend on p70S6K1 function 
or abundance but involves mTOR-rDNAp binding in a serum- and rapamycin-
dependant manner. (Paper IV) 
Pol II inhibition decreases rDNA transcription, likely in part via inhibition of factors 
needed for RNA pol I transcription. (Paper IV) 
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